199 related articles for article (PubMed ID: 27477028)
1. The effect of L-dopa in Parkinson's disease as revealed by neurophysiological studies of motor and sensory functions.
Suppa A; Bologna M; Conte A; Berardelli A; Fabbrini G
Expert Rev Neurother; 2017 Feb; 17(2):181-192. PubMed ID: 27477028
[TBL] [Abstract][Full Text] [Related]
2. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
[TBL] [Abstract][Full Text] [Related]
3. The Effect of L-Dopa/Carbidopa Intestinal Gel in Parkinson Disease Assessed Using Neurophysiologic Techniques.
Bologna M; Latorre A; Di Biasio F; Conte A; Belvisi D; Modugno N; Suppa A; Berardelli A; Fabbrini G
Clin Neuropharmacol; 2016; 39(6):302-305. PubMed ID: 27755134
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
5. Excitability of the lower-limb area of the motor cortex in Parkinson's disease.
Vacherot F; Attarian S; Eusebio A; Azulay JP
Neurophysiol Clin; 2010 Aug; 40(4):201-8. PubMed ID: 20674816
[TBL] [Abstract][Full Text] [Related]
6. Effect of deep brain stimulation and L-Dopa on electrocortical rhythms related to movement in Parkinson's disease.
Devos D; Defebvre L
Prog Brain Res; 2006; 159():331-49. PubMed ID: 17071241
[TBL] [Abstract][Full Text] [Related]
7. Early, severe and bilateral loss of LTP and LTD-like plasticity in motor cortex (M1) in de novo Parkinson's disease.
Kishore A; Joseph T; Velayudhan B; Popa T; Meunier S
Clin Neurophysiol; 2012 Apr; 123(4):822-8. PubMed ID: 21945457
[TBL] [Abstract][Full Text] [Related]
8. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
[TBL] [Abstract][Full Text] [Related]
9. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
10. Motor cortex plasticity can indicate vulnerability to motor fluctuation and high L-DOPA need in drug-naïve Parkinson's disease.
Kishore A; James P; Krishnan S; Yahia-Cherif L; Meunier S; Popa T
Parkinsonism Relat Disord; 2017 Feb; 35():55-62. PubMed ID: 28003105
[TBL] [Abstract][Full Text] [Related]
11. History of exposure to dopaminergic medication does not affect motor cortex plasticity and excitability in Parkinson's disease.
Kačar A; Filipović SR; Kresojević N; Milanović SD; Ljubisavljević M; Kostić VS; Rothwell JC
Clin Neurophysiol; 2013 Apr; 124(4):697-707. PubMed ID: 23085389
[TBL] [Abstract][Full Text] [Related]
12. L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients.
Cao C; Li D; Zhan S; Zhang C; Sun B; Litvak V
Neuroimage Clin; 2020; 26():102255. PubMed ID: 32361482
[TBL] [Abstract][Full Text] [Related]
13. Social intentions in Parkinson's disease patients: A kinematic study.
Straulino E; Scaravilli T; Castiello U
Cortex; 2015 Sep; 70():179-88. PubMed ID: 25804938
[TBL] [Abstract][Full Text] [Related]
14. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
15. Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Geng X; Wang X; Xie J; Zhang X; Wang X; Hou Y; Lei C; Li M; Han H; Yao X; Zhang Q; Wang M
Behav Brain Res; 2016 Dec; 315():1-9. PubMed ID: 27515286
[TBL] [Abstract][Full Text] [Related]
16. Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson's disease: clues from dyskinetic patients.
Kishore A; Popa T; Balachandran A; Chandran S; Pradeep S; Backer F; Krishnan S; Meunier S
Cereb Cortex; 2014 Aug; 24(8):2055-67. PubMed ID: 23535177
[TBL] [Abstract][Full Text] [Related]
17. Neurophysiological correlates of bradykinesia in Parkinson's disease.
Bologna M; Guerra A; Paparella G; Giordo L; Alunni Fegatelli D; Vestri AR; Rothwell JC; Berardelli A
Brain; 2018 Aug; 141(8):2432-2444. PubMed ID: 29901693
[TBL] [Abstract][Full Text] [Related]
18. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
Herz DM; Siebner HR; Hulme OJ; Florin E; Christensen MS; Timmermann L
Neuroimage; 2014 Apr; 90():15-23. PubMed ID: 24269570
[TBL] [Abstract][Full Text] [Related]
19. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
20. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.
Fabbri M; Coelho M; Guedes LC; Chendo I; Sousa C; Rosa MM; Abreu D; Costa N; Godinho C; Antonini A; Ferreira JJ
Parkinsonism Relat Disord; 2017 Jun; 39():37-43. PubMed ID: 28389156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
